KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Profit After Tax: 2018-2025

Historic Profit After Tax for Esperion Therapeutics (ESPR) over the last 8 years, with Sep 2025 value amounting to -$31.3 million.

  • Esperion Therapeutics' Profit After Tax fell 6.13% to -$31.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$105.8 million, marking a year-over-year decrease of 21.97%. This contributed to the annual value of -$51.7 million for FY2024, which is 75.27% up from last year.
  • Per Esperion Therapeutics' latest filing, its Profit After Tax stood at -$31.3 million for Q3 2025, which was down 146.23% from -$12.7 million recorded in Q2 2025.
  • Over the past 5 years, Esperion Therapeutics' Profit After Tax peaked at $61.0 million during Q1 2024, and registered a low of -$90.9 million during Q1 2021.
  • In the last 3 years, Esperion Therapeutics' Profit After Tax had a median value of -$40.5 million in 2025 and averaged -$31.4 million.
  • Per our database at Business Quant, Esperion Therapeutics' Profit After Tax surged by 198.87% in 2024 and then crashed by 166.30% in 2025.
  • MRQ analysis of 5 years shows Esperion Therapeutics' Profit After Tax stood at -$65.1 million in 2021, then increased by 14.79% to -$55.5 million in 2022, then decreased by 1.54% to -$56.3 million in 2023, then soared by 62.16% to -$21.3 million in 2024, then tumbled by 46.98% to -$31.3 million in 2025.
  • Its last three reported values are -$31.3 million in Q3 2025, -$12.7 million for Q2 2025, and -$40.5 million during Q1 2025.